https://www.prognyx.com/blog/clarity-s-cu-64-sar-bispsma-lands-first-psma-pet-breakthrough-designationPrognyxen2026-11-12Clarity's Cu-64 SAR-bisPSMA lands first PSMA-PET breakthrough designation https://www.prognyx.com/blog/j-j-s-tecvayli-talvey-phase-3-cuts-myeloma-progression-risk-as-early-as-second-lPrognyxen2026-11-11J J's TECVAYLI-TALVEY Phase 3 cuts myeloma progression risk as early as second line